Distinct Biochemical Profile in Human Thoracic Aneurysms with Associated Valve Dysfunction: Integrative Phosphoproteomic Analysis from the MultiTAAD Multiomic Database
Presented During:
Thursday, April 25, 2024: 5:38PM - 7:00PM
Sheraton Times Square
Posted Room Name:
Central Park
Abstract No:
P0106
Submission Type:
Abstract Submission
Authors:
Malak Elbatarny (1), Uros Kuzmanov (2), Daniella Eliathamby (3), Jennifer Chung (4), Craig Simmons (5), Anthony Gramolini (2), Maral Ouzounian (3)
Institutions:
(1) TGH / St Michael's, Toronto, ON, (2) University of Toronto, Toronto, NA, (3) Toronto General Hospital, Toronto, ON, (4) Toronto General Hospital, Toronto, Ontario, (5) University of Toronto, Toronto, Ontario
Submitting Author:
Malak Elbatarny
-
Contact Me
TGH / St Michael's
TGH / St Michael's
Co-Author(s):
Uros Kuzmanov
-
Contact Me
University of Toronto
University of Toronto
Daniella Eliathamby
-
Contact Me
Toronto General Hospital
Toronto General Hospital
Jennifer Chung
-
Contact Me
Toronto General Hospital
Toronto General Hospital
Craig Simmons
-
Contact Me
University of Toronto
University of Toronto
Anthony Gramolini
-
Contact Me
University of Toronto
University of Toronto
*Maral Ouzounian
-
Contact Me
Toronto General Hospital
Toronto General Hospital
Presenting Author:
Malak Elbatarny
-
Contact Me
TGH / St Michael's
TGH / St Michael's
Abstract:
Objective: Thoracic aortopathy (TAAD) often occurs with aortic valve pathology (stenosis, AS or regurgitation, AR) which may impact TAAD phenotype and severity. We compared proteomic and phosphoproteomic profiles of TAAD aortas with AS, AR, mixed (AS+AR), and normal valves to determine whether valve disease-associated aortopathy is phenotypically distinct.
Methods: 176 aortic samples (root, ascending, and arch) were collected prospectively from TAAD and dissection individuals with various aortic valve phenotypes (Figure 1A). All samples were analyzed using a novel deep-coverage protocol for mass spectrometry proteomics (data independent acquisition) and double enrichment technique to identify phosphorylation sites in detected proteins. Proteomic and phosphoproteomic data were directly compared by valve morphology (p<0.05 considered significant) to determine impact of valve function on aortopathy biochemical profile.
Results: Samples included N=123 males (74%) and mean age was 58±16. Among samples derived from individuals with concomitant valve disease, N=70 were AR-associated, N=41 were AS-associated, and N=11 were AS+AR. Considering the entire cohort, we quantified 6094 proteins and 2125 phosphorylation sites. At the proteomic level, when AS+AR was compared to normal valve-associated aortopathy, 721 proteins were differentially expressed (174 up in AS+AR, 547 down in AS+AR Figure 1B). Additionally, AR-associated aortopathy was associated with substantial phenotypic differences in both proteomic (total proteins 651; up in AR: 216; down in AR: 435) and phosphoproteomic data sets (total sites 210; hyperphosphorylated in AR: 96; hypophosphorylated in AR: 114 Figure 1B). Examining proteomic profiles in more detail, cytoskeletal proteins were predominantly decreased in AR-associated aortopathy while both hyper- and hypo-phosphorylation of cytoskeletal proteins was observed in AR (Figure 1C).
Conclusion: We performed the first multiproteomic analysis of aortopathy by aortic valve function on a large cohort of human samples using a novel protocol. Valve dysfunction, especially AR, is associated with altered aortic tissue biochemistry which suggests differences in mechanism and progression of aortopathy.
Methods: 176 aortic samples (root, ascending, and arch) were collected prospectively from TAAD and dissection individuals with various aortic valve phenotypes (Figure 1A). All samples were analyzed using a novel deep-coverage protocol for mass spectrometry proteomics (data independent acquisition) and double enrichment technique to identify phosphorylation sites in detected proteins. Proteomic and phosphoproteomic data were directly compared by valve morphology (p<0.05 considered significant) to determine impact of valve function on aortopathy biochemical profile.
Results: Samples included N=123 males (74%) and mean age was 58±16. Among samples derived from individuals with concomitant valve disease, N=70 were AR-associated, N=41 were AS-associated, and N=11 were AS+AR. Considering the entire cohort, we quantified 6094 proteins and 2125 phosphorylation sites. At the proteomic level, when AS+AR was compared to normal valve-associated aortopathy, 721 proteins were differentially expressed (174 up in AS+AR, 547 down in AS+AR Figure 1B). Additionally, AR-associated aortopathy was associated with substantial phenotypic differences in both proteomic (total proteins 651; up in AR: 216; down in AR: 435) and phosphoproteomic data sets (total sites 210; hyperphosphorylated in AR: 96; hypophosphorylated in AR: 114 Figure 1B). Examining proteomic profiles in more detail, cytoskeletal proteins were predominantly decreased in AR-associated aortopathy while both hyper- and hypo-phosphorylation of cytoskeletal proteins was observed in AR (Figure 1C).
Conclusion: We performed the first multiproteomic analysis of aortopathy by aortic valve function on a large cohort of human samples using a novel protocol. Valve dysfunction, especially AR, is associated with altered aortic tissue biochemistry which suggests differences in mechanism and progression of aortopathy.
Aortic Symposium:
Aortic Surgery Forum (Basic Aortic Research, Venue for Residents, Fellows, Junior Attendings)
Image or Table
